Frontiers in Pharmacology (Jun 2022)

Continual Deletion of Spinal Microglia Reforms Astrocyte Scar Favoring Axonal Regeneration

  • Longkuo Xia,
  • Longkuo Xia,
  • Longkuo Xia,
  • Longkuo Xia,
  • Jianhuan Qi,
  • Jianhuan Qi,
  • Jianhuan Qi,
  • Jianhuan Qi,
  • Mingming Tang,
  • Mingming Tang,
  • Mingming Tang,
  • Jing Liu,
  • Jing Liu,
  • Jing Liu,
  • Jing Liu,
  • Da Zhang,
  • Yanbing Zhu,
  • Baoyang Hu,
  • Baoyang Hu,
  • Baoyang Hu,
  • Baoyang Hu,
  • Baoyang Hu

DOI
https://doi.org/10.3389/fphar.2022.881195
Journal volume & issue
Vol. 13

Abstract

Read online

Astrocyte scar formation after spinal cord injury (SCI) efficiently limits the accurate damage but physically restricts the following axon regeneration. Lately, fine tuning scar formation is becoming a novel strategy to develop SCI treatment, yet how to leverage these opposite effects remains challenging. Here, utilizing an improved drug administration approach, we show that in a mouse model of spinal cord injury, continual deletion of microglia, especially upon scar formation, by pexidartinib decreases the amount of microglia-derived collagen I and reforms the astrocyte scar. The astrocytes become less compacted in the scar, which permits axon regeneration and extension. Although continual microglia deletion did not significantly improve the locomotive performance of the SCI mice, it did ameliorate their weight loss, possibly by improving their relevant health conditions. We thus identified a novel approach to regulate astrocyte scars for improved axon regeneration, which is indicative of the clinical treatment of SCI patients.

Keywords